Gowling WLG advised Precision NanoSystems, Inc. on the deal.
PNI received a contribution of $25.1M through the Strategic Innovation Fund. This round of funding will help support a $50M push to establish a bio-manufacturing centre in Vancouver. Slated to open within the next two years, the 40,000-square-foot facility will feature multiple suites with manufacturing lines for the end-to-end production of vaccines and genetic medicines.
Based in Vancouver, PNI is a world-leader in accelerating the creation of transformative medicine. Among other endeavours, the company’s Genetic Medicine Toolkit enables researchers around the world to effectively translate new disease insights into non-viral genetic medicines. PNI markets its products to global pharmaceutical and biotechnology companies, as well as a number of leading academic institutions.
Paul Armitage (Picture), partner and head of Vancouver’s Technology Industry Group, advised on the deal.
Involved fees earner: Paul Armitage – Gowling WLG;
Law Firms: Gowling WLG;
Clients: Precision NanoSystems, Inc. ;